Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era? - PubMed (original) (raw)
. 2007 Aug;178(2):459-63; discussion 463.
doi: 10.1016/j.juro.2007.03.124. Epub 2007 Jun 11.
Affiliations
- PMID: 17561132
- DOI: 10.1016/j.juro.2007.03.124
Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
R Houston Thompson et al. J Urol. 2007 Aug.
Erratum in
- J Urol. 2007 Nov;178(5):2224
Abstract
Purpose: The GPSM (Gleason, prostate specific antigen, seminal vesicle and margin status) scoring algorithm is a user friendly model for predicting biochemical recurrence following radical retropubic prostatectomy. It was developed from patients who underwent radical retropubic prostatectomy from 1990 to 1993. We investigated the predictive ability of GPSM in the contemporary era.
Materials and methods: We identified 2,728 patients who underwent radical retropubic prostatectomy for prostate cancer from 1997 to 2000 at our institution. Cox proportional hazard regression models were used to develop multivariate scoring algorithms. Harrell's measure of concordance was used to compare the competing models.
Results: In the contemporary era each GPSM feature remained significantly associated with biochemical recurrence in a multivariate model (each p <0.001). Harrell's measure of concordance for the algorithm was 0.706 vs 0.718 in the original study. After adjusting for GPSM on multivariate analysis Gleason primary 4/5 (p <0.001), DNA ploidy (p = 0.018) and tumor size (p <0.001) were associated with biochemical recurrence. However, none of these features increased Harrell's measure of concordance greater than 0.01 when added to the GPSM model. In addition, using the original 1990 to 1993 cohort, 495 patients with a GPSM score of 10 or greater were significantly more likely to die of prostate cancer compared with 2,169 with a GPSM score of less than 10 (at 15 years 13% vs 2%, HR 6.5, p <0.001).
Conclusions: The GPSM scoring algorithm is a simple predictive model that remains associated with biochemical recurrence in the contemporary era. In addition, to our knowledge the GPSM algorithm is the first nomogram associated with survival in patients with prostate cancer.
Similar articles
- Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Blute ML, et al. J Urol. 2001 Jan;165(1):119-25. doi: 10.1097/00005392-200101000-00030. J Urol. 2001. PMID: 11125379 - Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Han M, et al. J Urol. 2003 Feb;169(2):517-23. doi: 10.1097/01.ju.0000045749.90353.c7. J Urol. 2003. PMID: 12544300 - Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE, Roehl KA, Smith ND, Antenor JA, Han M, Catalona WJ. Eggener SE, et al. J Urol. 2005 Apr;173(4):1150-5. doi: 10.1097/01.ju.0000155158.79489.48. J Urol. 2005. PMID: 15758725 - A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis.
O'Brien BA, Cohen RJ, Wheeler TM, Moorin RE. O'Brien BA, et al. BJU Int. 2011 Feb;107(3):389-95. doi: 10.1111/j.1464-410X.2010.09539.x. Epub 2010 Aug 12. BJU Int. 2011. PMID: 20707795 Review. - Benign positive margins after radical prostatectomy means a poor prognosis--con.
Rubin MA, Montie JE. Rubin MA, et al. Urology. 2005 Feb;65(2):221-3. doi: 10.1016/j.urology.2004.08.002. Urology. 2005. PMID: 15708026 Review. No abstract available.
Cited by
- A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.
Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM. Ross AE, et al. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):64-9. doi: 10.1038/pcan.2013.49. Epub 2013 Oct 22. Prostate Cancer Prostatic Dis. 2014. PMID: 24145624 Free PMC article. - Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.
Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB. Karnes RJ, et al. J Urol. 2013 Dec;190(6):2047-53. doi: 10.1016/j.juro.2013.06.017. Epub 2013 Jun 11. J Urol. 2013. PMID: 23770138 Free PMC article. - Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.
Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY. Vanaja DK, et al. Cancer Invest. 2009 Jun;27(5):549-60. doi: 10.1080/07357900802620794. Cancer Invest. 2009. PMID: 19229700 Free PMC article. - The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort.
Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC. Nabhan M, et al. Mayo Clin Proc. 2012 Jun;87(6):540-7. doi: 10.1016/j.mayocp.2012.01.017. Mayo Clin Proc. 2012. PMID: 22677074 Free PMC article. - Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.
Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW, Veltri RW. Isharwal S, et al. Int J Cancer. 2008 Dec 1;123(11):2636-43. doi: 10.1002/ijc.23838. Int J Cancer. 2008. PMID: 18767043 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical